14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:TSRO
Delisted

TESARO Fund Price (Quote)

$74.96
+0 (+0%)
At Close: Feb 13, 2019

Range Low Price High Price Comment
30 days $0.0060 $169.56 Wednesday, 13th Feb 2019 TSRO stock ended at $74.96. During the day the stock fluctuated 0% from a day low at $74.96 to a day high of $74.96.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical TESARO prices

Date Open High Low Close Volume
Jul 10, 2018 $44.60 $45.48 $43.50 $44.85 880 886
Jul 09, 2018 $45.20 $45.45 $43.40 $44.11 985 911
Jul 06, 2018 $43.35 $45.29 $43.25 $45.17 1 019 649
Jul 05, 2018 $43.25 $43.59 $42.00 $43.23 1 473 236
Jul 03, 2018 $41.53 $43.75 $41.22 $43.52 759 838
Jul 02, 2018 $42.92 $43.58 $40.01 $41.56 3 038 347
Jun 29, 2018 $44.46 $45.74 $43.62 $44.47 1 458 198
Jun 28, 2018 $43.70 $44.80 $42.70 $44.23 1 290 989
Jun 27, 2018 $44.66 $45.30 $43.20 $43.58 1 750 846
Jun 26, 2018 $45.72 $46.00 $42.14 $43.39 2 353 913
Jun 25, 2018 $47.99 $47.99 $45.21 $45.70 2 028 737
Jun 22, 2018 $45.82 $49.89 $45.58 $49.62 3 525 824
Jun 21, 2018 $46.08 $46.72 $43.75 $45.75 2 862 872
Jun 20, 2018 $43.50 $47.81 $43.29 $46.49 8 778 797
Jun 19, 2018 $39.31 $40.43 $38.57 $39.99 1 721 780
Jun 18, 2018 $39.38 $39.84 $38.40 $39.38 1 458 931
Jun 15, 2018 $41.03 $41.17 $39.45 $39.77 3 209 798
Jun 14, 2018 $43.17 $43.62 $40.80 $41.43 2 364 593
Jun 13, 2018 $42.47 $44.41 $41.69 $42.85 2 358 684
Jun 12, 2018 $42.75 $44.00 $42.15 $42.44 1 602 574
Jun 11, 2018 $43.32 $43.89 $42.02 $42.70 1 805 360
Jun 08, 2018 $44.74 $45.60 $43.19 $43.67 1 446 394
Jun 07, 2018 $44.21 $46.14 $43.91 $45.42 1 533 168
Jun 06, 2018 $42.87 $44.14 $42.55 $43.98 1 415 361
Jun 05, 2018 $43.17 $44.04 $42.38 $42.56 1 874 171
Click to get the best stock tips daily for free!

About TESARO

TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly p... TSRO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT